Skip to main content
Top
Published in: Lung 1/2017

01-02-2017

Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review

Authors: Shalvaree Vaidya, Clare L. Hibbert, Elizabeth Kinter, Stefan Boes

Published in: Lung | Issue 1/2017

Login to get access

Abstract

Background

Idiopathic pulmonary fibrosis (IPF) is an incurable, debilitating disease which impairs lung function and eventually leads to death. Currently, there is a lack of effective modifying therapies and treatments for IPF as the underlying epidemiological mechanism is not clearly understood. This leads to difficulty in diagnosing and managing IPF, which results in a high incurment of disease-associated cost. Even though IPF poses a substantial economic burden, there is a lack of research available on cost triggers and healthcare utilization, which can be a barrier to future economic evaluations of new medicines for IPF.

Objectives

We aimed to conduct a systematic literature review (SLR) to identify the key cost-generating events of IPF and to gather any related costing information.

Results

The data showed that the main events triggering high resource use in patients were the symptoms of IPF progression along with comorbidities and lung transplantations. These events result in a high economic impact through the use of medications, health care professionals, and hospital stays.

Conclusion

More research is needed to identify the direct, and indirect, relationships between IPF events and the costs they generate. This would help to further evaluate the area of need for future health technologies and to understand what events should be targeted to reduce the global economic burden of IPF.
Appendix
Available only for authorised users
Literature
1.
go back to reference Loveman E, Copley VR, Colquitt J, Scott DA, Clegg A, Jones J, O’Reilly KM, Singh S, Bausewein C, Wells A (2015) The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation. Health Technol Assess 19:1–336 i–xxivCrossRefPubMedPubMedCentral Loveman E, Copley VR, Colquitt J, Scott DA, Clegg A, Jones J, O’Reilly KM, Singh S, Bausewein C, Wells A (2015) The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation. Health Technol Assess 19:1–336 i–xxivCrossRefPubMedPubMedCentral
2.
go back to reference Panos RJ, Mortenson RL, Niccoli SA, King TE Jr (1990) Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 88:396–404CrossRefPubMed Panos RJ, Mortenson RL, Niccoli SA, King TE Jr (1990) Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 88:396–404CrossRefPubMed
3.
go back to reference Collard HR, Ward AJ, Lanes S, Cortney Hayflinger D, Rosenberg DM, Hunsche E (2012) Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 15:829–835CrossRefPubMed Collard HR, Ward AJ, Lanes S, Cortney Hayflinger D, Rosenberg DM, Hunsche E (2012) Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 15:829–835CrossRefPubMed
4.
go back to reference Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRefPubMed Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRefPubMed
5.
go back to reference Kistler KD, Nalysnyk L, Rotella P, Esser D (2014) Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med 14:1–12CrossRef Kistler KD, Nalysnyk L, Rotella P, Esser D (2014) Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med 14:1–12CrossRef
6.
go back to reference Lee AS, Mira-Avendano I, Ryu JH, Daniels CE (2014) The burden of idiopathic pulmonary fibrosis: an unmet public health need. Respir Med 108:955–967CrossRefPubMed Lee AS, Mira-Avendano I, Ryu JH, Daniels CE (2014) The burden of idiopathic pulmonary fibrosis: an unmet public health need. Respir Med 108:955–967CrossRefPubMed
7.
go back to reference Hutchinson J, Fogarty A, Hubbard R, McKeever T (2015) Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 46:795–806CrossRefPubMed Hutchinson J, Fogarty A, Hubbard R, McKeever T (2015) Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 46:795–806CrossRefPubMed
8.
go back to reference Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100CrossRefPubMedPubMedCentral Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100CrossRefPubMedPubMedCentral
9.
go back to reference Johnston K, Buxton M, Jones D, Fitzpatrick R (1999) Assessing the costs of healthcare technologies in clinical trials. Health Technol Assess, vol. 3 Johnston K, Buxton M, Jones D, Fitzpatrick R (1999) Assessing the costs of healthcare technologies in clinical trials. Health Technol Assess, vol. 3
10.
go back to reference Boccuzzi SJ (2003) Indirect health care costs. In: Weintraub WS (ed) Cardiovascular health care economics. Humana Press, Totowa, NJ, pp 63–79CrossRef Boccuzzi SJ (2003) Indirect health care costs. In: Weintraub WS (ed) Cardiovascular health care economics. Humana Press, Totowa, NJ, pp 63–79CrossRef
11.
go back to reference Statistics, B.o.L. (2015) Consumer price index-all urban consumers Statistics, B.o.L. (2015) Consumer price index-all urban consumers
12.
go back to reference Collard HR, Chen SY, Yeh WS, Li Q, Lee YC, Wang A, Raghu G (2015) Health care utilization and costs in idiopathic pulmonary fibrosis in United States medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc 12:981–987CrossRefPubMed Collard HR, Chen SY, Yeh WS, Li Q, Lee YC, Wang A, Raghu G (2015) Health care utilization and costs in idiopathic pulmonary fibrosis in United States medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc 12:981–987CrossRefPubMed
13.
go back to reference NICE (2013) Idiopathic pulmonary fibrosis costing report. National Institute for Health and Care Excellence, Manchester NICE (2013) Idiopathic pulmonary fibrosis costing report. National Institute for Health and Care Excellence, Manchester
14.
go back to reference Loveman E, Copley VR, Colquitt JL, Scott DA, Clegg AJ, Jones J, O’Reilly KM, Singh S, Bausewein C, Wells A (2014) The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol 15:63CrossRefPubMedPubMedCentral Loveman E, Copley VR, Colquitt JL, Scott DA, Clegg AJ, Jones J, O’Reilly KM, Singh S, Bausewein C, Wells A (2014) The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol 15:63CrossRefPubMedPubMedCentral
15.
go back to reference Lee JS, McLaughlin S, Collard HR (2011) Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med 17:348–354CrossRefPubMed Lee JS, McLaughlin S, Collard HR (2011) Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med 17:348–354CrossRefPubMed
16.
go back to reference Chen S-Y, Collard HR, Yeh W-S, Li Q, Lee Y-C, Wang A, Raghu G, International B Francisco U.o.C.S. and Evidera (2014) An analysis of US medicare beneficiaries: Burden of direct medical costs in patients with idiopathic pulmonary fibrosis. In: ISPOR 17th Annual European Congress, Amsterdam, The Netherlands Chen S-Y, Collard HR, Yeh W-S, Li Q, Lee Y-C, Wang A, Raghu G, International B Francisco U.o.C.S. and Evidera (2014) An analysis of US medicare beneficiaries: Burden of direct medical costs in patients with idiopathic pulmonary fibrosis. In: ISPOR 17th Annual European Congress, Amsterdam, The Netherlands
17.
go back to reference Chen SY, Collard HR, Yeh WS, Li Q, Lee YC, Wang A, Raghu G (2014) PRS26—an analysis of US medicare beneficiaries: burden of direct medical costs in patients with idiopathic pulmonary fibrosis. Value Health 17:A592CrossRefPubMed Chen SY, Collard HR, Yeh WS, Li Q, Lee YC, Wang A, Raghu G (2014) PRS26—an analysis of US medicare beneficiaries: burden of direct medical costs in patients with idiopathic pulmonary fibrosis. Value Health 17:A592CrossRefPubMed
18.
go back to reference Wilson EC, Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Twentyman OP, Wilson AM (2014) Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial. Pharmacoeconomics 32:87–99CrossRefPubMed Wilson EC, Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Twentyman OP, Wilson AM (2014) Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial. Pharmacoeconomics 32:87–99CrossRefPubMed
19.
go back to reference Wu N, Yu YF, Chuang CC, Wang R, Benjamin NN, Coultas DB (2015) Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States. J Med Econ 18:249–257CrossRefPubMed Wu N, Yu YF, Chuang CC, Wang R, Benjamin NN, Coultas DB (2015) Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States. J Med Econ 18:249–257CrossRefPubMed
20.
go back to reference George TJ, Arnaoutakis GJ, Shah AS (2011) LUng transplant in idiopathic pulmonary fibrosis. Arch Surg 146:1204–1209CrossRefPubMed George TJ, Arnaoutakis GJ, Shah AS (2011) LUng transplant in idiopathic pulmonary fibrosis. Arch Surg 146:1204–1209CrossRefPubMed
21.
22.
go back to reference Nathan SD, Noble PW, Tuder RM (2007) Idiopathic pulmonary fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 175:875–880CrossRefPubMed Nathan SD, Noble PW, Tuder RM (2007) Idiopathic pulmonary fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 175:875–880CrossRefPubMed
23.
go back to reference Lancaster LH, Mason WR, Parnell JA, Rice TW, Loyd JE, Milstone AP, Collard HR, Malow BA (2009) Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 136:772–778CrossRefPubMedPubMedCentral Lancaster LH, Mason WR, Parnell JA, Rice TW, Loyd JE, Milstone AP, Collard HR, Malow BA (2009) Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 136:772–778CrossRefPubMedPubMedCentral
24.
go back to reference Zhuo X, Zhang P, Hoerger TJ (2013) Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med 45:253–261CrossRefPubMed Zhuo X, Zhang P, Hoerger TJ (2013) Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med 45:253–261CrossRefPubMed
25.
go back to reference Excellence, N.I.f.H.a.C. (2015) Nintedanib for treating idiopathic pulmonary fibrosis NICE Excellence, N.I.f.H.a.C. (2015) Nintedanib for treating idiopathic pulmonary fibrosis NICE
26.
go back to reference Eliot O-T, Yanxin W, Bonni H, Hongwei W, Juliette M (2012) the economic burden of idiopathic pulmonary fibrosis from diagnosis to lung transplant. In: A40, the economic burden of respiratory disease and cost-effectiveness of treatments, American Thoracic Society, pp A1497–A1497 Eliot O-T, Yanxin W, Bonni H, Hongwei W, Juliette M (2012) the economic burden of idiopathic pulmonary fibrosis from diagnosis to lung transplant. In: A40, the economic burden of respiratory disease and cost-effectiveness of treatments, American Thoracic Society, pp A1497–A1497
27.
go back to reference Hagaman JT, Kinder BW, Eckman MH (2010) Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung 188:125–132CrossRefPubMed Hagaman JT, Kinder BW, Eckman MH (2010) Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung 188:125–132CrossRefPubMed
28.
go back to reference Tzouvelekis A, Bonella F, Spagnolo P (2015) Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag 11:359–370PubMedPubMedCentral Tzouvelekis A, Bonella F, Spagnolo P (2015) Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag 11:359–370PubMedPubMedCentral
29.
go back to reference Excellence N.I.f.H.a.C (2013) Pirfenidone for treating idiopathic pulmonary fibrosis. In: Final appraisal determination, NICE Excellence N.I.f.H.a.C (2013) Pirfenidone for treating idiopathic pulmonary fibrosis. In: Final appraisal determination, NICE
30.
go back to reference Ferreira LM (2014) Two new IPF treatments will reportedly will cost between $94 K and $96 K a year Ferreira LM (2014) Two new IPF treatments will reportedly will cost between $94 K and $96 K a year
Metadata
Title
Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review
Authors
Shalvaree Vaidya
Clare L. Hibbert
Elizabeth Kinter
Stefan Boes
Publication date
01-02-2017
Publisher
Springer US
Published in
Lung / Issue 1/2017
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-016-9960-6

Other articles of this Issue 1/2017

Lung 1/2017 Go to the issue